Price T Rowe Associates Inc Novavax Inc Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Novavax Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 56,065 shares of NVAX stock, worth $776,500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
56,065
Previous 47,937
16.96%
Holding current value
$776,500
Previous $231,000
16.45%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding NVAX
# of Institutions
246Shares Held
75.8MCall Options Held
5.06MPut Options Held
7.19M-
State Street Corp Boston, MA16.9MShares$234 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.5MShares$187 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.43MShares$131 Million0.0% of portfolio
-
Shah Capital Management8.12MShares$112 Million19.75% of portfolio
-
Geode Capital Management, LLC Boston, MA2.59MShares$35.8 Million0.0% of portfolio
About NOVAVAX INC
- Ticker NVAX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,215,104
- Market Cap $1.08B
- Description
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...